TeselaGen is an enterprise software company that makes its home in the software hub of San Francisco, California. Our diverse team of molecular biologists, computer scientists, physicists and engineers hail from the University of California, Stanford, Harvard, and both Catolicá University and the University of Chile in Santiago, Chile.
At TeselaGen, we are building the information technology backbone for synthetic biology. Our mission is to provide a secure, scalable enterprise platform for modern molecular biology approaches to the production of medicines, enzymes and agricultural products. Our customers range from large Fortune 50 companies to individual academic researchers.
Mike Fero, Ph.D.
Founder, Chief Executive Officer
Mike Fero was an NIH Quantitative Research Career Fellow and principal investigator at Stanford, studying the role of protein localization and the essential genomic elements needed for bacterial life. With Pat Brown and David Botstein Michael directed the development of the first full-genome human DNA microarrays. Before joining Stanford, he was VP of Software Engineering at Neomorphic, a computational genomics company acquired by Affymetrix, and a consulting scientist at Hyperparallel, a data mining company acquired by Yahoo!. Mike has over 40 publications in peer-reviewed journals and holds a Ph.D. in Elementary Particle Physics from the University of California at Irvine.
Eduardo Abeliuk, Ph.D.
Founder, Chief Technology Officer
Dr. Abeliuk received his Ph.D. studying how bacterial cells divide using high-throughput genetic and molecular biology techniques. His work has been published by multiple international journals and holds patent app. USSN 61/501,073. While at Stanford, he started, built and sold KissMe LLC and also founded Classroom.tv, Inc. KissMe was an application that hit a million users within the first few weeks and was acquired in 2009. Prior coming to Stanford, Eduardo was at SMaL Camera Tech., an MIT startup acquired by Cypress Semi. He also interned at Motorola, Synopsys and Lightspeed Venture Partners. Eduardo holds a Ph.D. in Electrical Engineering from Stanford University.
Nathan Hillson, Ph.D.
Founder, Chief Scientific Officer
Dr. Hillson is the Director of Synthetic Biology Informatics, Fuels Synthesis and Technologies Divisions, at the U.S. Department of Energy’s Joint BioEnergy Institute. Hillson is also the Principal Investigator of the Department of Energy’s Agile BioFoundry; the Group Lead of Synthetic Biology Informatics at the Department of Energy’s Joint Genome Institute; Computational Staff Scientist and Department Head of Biodesign in the Biological Systems and Engineering Division at Lawrence Berkeley National Laboratory; and Affiliate Investigator at the Engineering Biology Research Center (EBRC). He holds a PhD in Biophysics from Harvard.
Adam Arkin, Ph.D.
Dr. Arkin is Director of the Berkeley Synthetic Biology Institute and is the Dean A. Richard Newton Memorial Professor in UC Berkeley’s Department of Bioengineering. He is also the scientific lead of two large Department of Energy projects: ENIGMA which seeks to discover, characterize and harness and microbial communities that impact the fate of contaminants in soil and water; and the Systems Biology Knowledgebase a collaborative, open environment for systems and synthetic biology of plants, microbes and their communities. His research centers on uncovering the evolutionary design principles of cellular networks and populations and exploiting them for applications in health, the environment, and bioenergy. He is the recipient of the 2013 Ernest Orlando Lawrence Award, the Department of Energy (DOE)’s highest scientific honor. He was named a Fellow of the American Academy of Microbiology in 2007, and has been profiled in Time Magazine as a “future innovator". A member of the University of California at Berkeley faculty since 1999, he earned his Ph.D. in Physical Chemistry from Massachusetts Institute of Technology.
Keith Wilson, Ph.D.
Dr. Keith Wilson is the Chief Science Officer at Oxford BioTherapeutics. Keith has led research efforts at PDL BioPharma through the corporate transition into Facet Biotech, Abbott Laboratories, Abbvie, and now Oxford. He has led internal scientific and business reviews of pipeline portfolio and strategy leading to corporate directional change and has been responsible for implementation of new pipeline strategies. He was a Postdoctoral Fellow at Stanford University and later the Director of Computational Biology and Genomics at EOS Biotechnology and PDL BioPharma. Dr. Wilson holds Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University.
Sarah Richardson, Ph.D.
Dr. Sarah Richardson hails from west Baltimore. She earned a B.S. in biology from the University of Maryland in 2004 and a Ph.D. in human genetics and molecular biology from Johns Hopkins University School of Medicine in 2011. She specializes in the design of genomes: as a DOE Computational Graduate Fellow she designed a synthetic yeast genome; as a Distinguished Postdoctoral Fellow of Genomics at the Department of Energy's Lawrence Berkeley National Laboratory she worked on massive scale synthetic biology projects and the integration of computational genomics with experimental genomics; and as Chief Scientist of Ignition Genomics she leads the construction of genomic toolkits for non-model prokaryotes. Trained in both computational and molecular biology, she has a unique perspective on the emerging technologies made possible by “synthetic” biology.